JNJ
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released on January 21, 2026, the New Brunswick-based titan signaled a definitive pivot toward high-growth markets in oncology and cardiovascular technology.